US Bancorp DE Reduces Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• US Bancorp DE reduced its stake in Thermo Fisher Scientific by 2.4%, owning 173,633 shares valued at approximately $70.4 million after selling 4,300 shares in the second quarter.
• Thermo Fisher Scientific recently reported earnings of $5.36 per share, exceeding analysts' expectations, with revenues of $10.86 billion for the quarter, representing a 2.9% increase year-over-year.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Thermo Fisher Scientific, with a target price averaging $593.43, reflecting positive sentiment amongst investors.

US Bancorp DE trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 173,633 shares of the medical research company's stock after selling 4,300 shares during the quarter. US Bancorp DE's holdings in Thermo Fisher Scientific were worth $70,402,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Thermo Fisher Scientific by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock valued at $16,659,627,000 after purchasing an additional 230,382 shares during the period. Amundi raised its position in shares of Thermo Fisher Scientific by 5.9% in the first quarter. Amundi now owns 3,029,044 shares of the medical research company's stock valued at $1,426,316,000 after purchasing an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Thermo Fisher Scientific by 4.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after purchasing an additional 115,463 shares during the period. Pictet Asset Management Holding SA increased its holdings in Thermo Fisher Scientific by 7.2% during the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after acquiring an additional 193,378 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Thermo Fisher Scientific by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after acquiring an additional 329,974 shares during the period. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 0.2%

Shares of TMO opened at $534.92 on Friday. The stock has a market capitalization of $201.99 billion, a P/E ratio of 30.94, a PEG ratio of 2.91 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The firm has a fifty day simple moving average of $487.44 and a two-hundred day simple moving average of $448.31. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the prior year, the company posted $5.37 EPS. The firm's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on TMO shares. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a report on Friday, July 11th. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, October 4th. HSBC reaffirmed a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Thermo Fisher Scientific in a research note on Saturday, September 27th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $593.43.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 in the last three months. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.